Nature-Derived DPP-4 Inhibitors: A Promising Alternative for Management of Diabetes Mellitus
Аннотация
Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely prescribed antihyperglycemic agents, used as monotherapy or in combination with other treatments for diabetes and its associated complications. However, synthetic DPP-4 inhibitors may cause adverse effects, including hypoglycemia, pancreatic inflammation, endothelial dysfunction, and hypersensitivity reactions. Consequently, naturally derived DPP-4 inhibitors are receiving increasing attention as potential alternatives or sources of lead compounds. Biological sources, particularly plants, aquatic organisms, and microorganisms, provide diverse bioactive constituents that may inhibit DPP-4 while also enhancing insulin secretion, reducing lipid peroxidation and hyperlipidemia, and improving antioxidant defenses. This review summarizes more than 200 bioactive compounds and peptides reported to exhibit DPP-4 inhibitory activity from diverse biological sources. The reviewed constituents include phenolics, flavonoids such as 5-hydroxy-7,8-dimethoxyflavone and phlorizin, alkaloids such as berberine and columbamine, terpenoids such as macrocarpal C and β-pinene, steroids such as stellasterol, fatty acids such as myristic and palmitic acids, and peptides such as diprotin A. These candidates have been reported, evaluated, or investigated using computational approaches, biochemical assays, in vitro studies, and/or in vivo models. The review highlights their potential as lead molecules for functional foods and novel antidiabetic therapeutics. Nevertheless, challenges related to bioavailability, pharmacokinetics, toxicity, standardization, and limited clinical evidence remain. Further pharmacological, toxicological, pharmacokinetic, and clinical studies are essential to establish their efficacy and safety. Graphical Abstract